JP2024505680A5 - - Google Patents
Info
- Publication number
- JP2024505680A5 JP2024505680A5 JP2023547408A JP2023547408A JP2024505680A5 JP 2024505680 A5 JP2024505680 A5 JP 2024505680A5 JP 2023547408 A JP2023547408 A JP 2023547408A JP 2023547408 A JP2023547408 A JP 2023547408A JP 2024505680 A5 JP2024505680 A5 JP 2024505680A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- combination according
- administered
- cancer
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163146369P | 2021-02-05 | 2021-02-05 | |
| US202163146349P | 2021-02-05 | 2021-02-05 | |
| US202163146352P | 2021-02-05 | 2021-02-05 | |
| US202163146357P | 2021-02-05 | 2021-02-05 | |
| US202163146395P | 2021-02-05 | 2021-02-05 | |
| US202163146376P | 2021-02-05 | 2021-02-05 | |
| US63/146,352 | 2021-02-05 | ||
| US63/146,395 | 2021-02-05 | ||
| US63/146,357 | 2021-02-05 | ||
| US63/146,369 | 2021-02-05 | ||
| US63/146,349 | 2021-02-05 | ||
| US63/146,376 | 2021-02-05 | ||
| US202163185651P | 2021-05-07 | 2021-05-07 | |
| US202163185672P | 2021-05-07 | 2021-05-07 | |
| US202163185704P | 2021-05-07 | 2021-05-07 | |
| US202163185695P | 2021-05-07 | 2021-05-07 | |
| US63/185,695 | 2021-05-07 | ||
| US63/185,704 | 2021-05-07 | ||
| US63/185,651 | 2021-05-07 | ||
| US63/185,672 | 2021-05-07 | ||
| PCT/US2022/015262 WO2022170060A1 (en) | 2021-02-05 | 2022-02-04 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505680A JP2024505680A (ja) | 2024-02-07 |
| JP2024505680A5 true JP2024505680A5 (https=) | 2025-02-13 |
Family
ID=82741881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023547408A Pending JP2024505680A (ja) | 2021-02-05 | 2022-02-04 | 異常な細胞成長を処置するための併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240115571A1 (https=) |
| EP (1) | EP4288057A4 (https=) |
| JP (1) | JP2024505680A (https=) |
| KR (1) | KR20230142757A (https=) |
| AU (1) | AU2022216284A1 (https=) |
| BR (1) | BR112023015616A2 (https=) |
| CA (1) | CA3210506A1 (https=) |
| IL (1) | IL304908A (https=) |
| MX (1) | MX2023009223A (https=) |
| WO (1) | WO2022170060A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| MX2023012929A (es) * | 2021-05-05 | 2023-11-13 | Huyabio Int Llc | Terapias de combinacion que comprenden inhibidores de shp2 e inhibidores de tirosina cinasa egfr. |
| US20250041298A1 (en) * | 2021-12-02 | 2025-02-06 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| IL313653A (en) * | 2022-01-06 | 2024-08-01 | Immuneering Corp | Immuno-oncology inhibitors of MEK and their therapeutic uses |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| CA3262155A1 (en) | 2022-08-11 | 2024-02-15 | Evexta Bio | COMPOUNDS FOR CANCER TREATMENT |
| WO2024148307A1 (en) * | 2023-01-06 | 2024-07-11 | Erasca, Inc. | Raf inhibitor and erk1/2 and/or shp2 inhibitor combination therapy |
| WO2025010287A2 (en) * | 2023-07-03 | 2025-01-09 | Immuneering Corporation | Mek immune oncology inhibitors and therapeutic uses thereof |
| CN116509868B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合bay293的应用及药物组合物 |
| WO2025168601A1 (en) | 2024-02-05 | 2025-08-14 | Evexta Bio | Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases |
| WO2025202854A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120289A1 (en) * | 2014-02-07 | 2015-08-13 | Verastem, Inc. | Methods and compositions for treating abnormal cell growth |
| KR20170060042A (ko) * | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| US20190367964A1 (en) * | 2016-02-02 | 2019-12-05 | Dana-Farber Cancer Institute, Inc. | Dissociation of human tumor to single cell suspension followed by biological analysis |
| WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| US11633401B2 (en) * | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
| CN112137994B (zh) * | 2020-09-15 | 2022-10-14 | 中山大学 | 小分子化合物在制备抗丝状病毒药物中的应用 |
-
2022
- 2022-02-04 JP JP2023547408A patent/JP2024505680A/ja active Pending
- 2022-02-04 KR KR1020237029729A patent/KR20230142757A/ko active Pending
- 2022-02-04 WO PCT/US2022/015262 patent/WO2022170060A1/en not_active Ceased
- 2022-02-04 AU AU2022216284A patent/AU2022216284A1/en not_active Abandoned
- 2022-02-04 EP EP22750444.6A patent/EP4288057A4/en active Pending
- 2022-02-04 BR BR112023015616A patent/BR112023015616A2/pt unknown
- 2022-02-04 CA CA3210506A patent/CA3210506A1/en active Pending
- 2022-02-04 MX MX2023009223A patent/MX2023009223A/es unknown
- 2022-02-04 IL IL304908A patent/IL304908A/en unknown
- 2022-02-04 US US18/263,820 patent/US20240115571A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024505680A5 (https=) | ||
| van der Kleij et al. | Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology: MBA van der Kleij et al. | |
| Motzer et al. | Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology | |
| Bedard et al. | A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | |
| Tolcher et al. | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors | |
| Wright et al. | Trametinib: first global approval | |
| Kulke et al. | A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors | |
| Jin et al. | Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer | |
| Deming et al. | A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer | |
| JP2024540015A5 (https=) | ||
| Huijberts et al. | Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer | |
| JP2019532051A5 (https=) | ||
| JP2022533578A5 (https=) | ||
| EP3089747A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| Liang et al. | A pilot study of apatinib as third-line treatment in patients with heavily treated metastatic colorectal cancer | |
| TW201839399A (zh) | 癌症治療 | |
| Lee et al. | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations | |
| Giopanou et al. | RAS and BRAF in the foreground for non-small cell lung cancer and colorectal cancer: Similarities and main differences for prognosis and therapies | |
| TW202402290A (zh) | 癌症治療 | |
| Loh et al. | Targeted therapy based on tumor genomic analyses in metastatic urachal carcinoma | |
| WO2022150628A1 (en) | Use of a kras g12c inhibitor in treating cancers | |
| Wang et al. | Preclinical investigation of orally bioavailable, potent KRAS Multi inhibitor JAB-23425 | |
| Peng et al. | Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy | |
| Chew et al. | Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors | |
| Terheyden et al. | Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma |